University Hospital of South Manchester
Welcome,         Profile    Billing    Logout  
 24 Trials 
16 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Whorwell, Peter
EGIS, NCT05157061: GOS to Reduce Symptom Severity in IBS

Completed
N/A
153
Europe
Galacto-oligosaccharides (GOS), Prebiotic, Maltodextrine, Placebo
Clasado, CR2O B.V.
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
08/24
08/24
Bundred, Nigel
EPHOS-B, NCT01104571 / 2008-005466-30: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Checkmark P3 trial design
Dec 2011 - Dec 2011: P3 trial design
Active, not recruiting
3
257
Europe
trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis
Breast Cancer
08/17
09/25
IDBC, NCT04495244: A Study to Identify Breast Cancer

Recruiting
N/A
600
Europe
Syantra DX Breast Cancer
Syantra Inc.
Breast Cancer Female
12/21
12/22
Singh, Dave
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma ().

Active, not recruiting
3
837
Europe, RoW
CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant
Chiesi Farmaceutici S.p.A.
Asthma
07/25
09/25
COURSE, NCT04039113 / 2019-001363-67: Tezepelumab COPD Exacerbation Study

Jan 2024 - Dec 2024: Data from COURSE trial for COPD
Completed
2
337
Europe, Canada, US, RoW
Tezepelumab, Placebo
AstraZeneca, Amgen
Chronic Obstructive Pulmonary Disease (COPD)
11/23
01/24
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting
1/2
45
Europe
CHF6333, CHF6333 Placebo
Chiesi Farmaceutici S.p.A.
Bronchiectasis
06/25
06/25
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Completed
1
110
Europe
AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
AstraZeneca
Asthma
01/23
01/23
KN-002, NCT05006521: Single and Multiple Ascending Dose Study of

Completed
1
117
Europe
KN-002
Kinaset Therapeutics Inc
Asthma COPD
12/23
07/24
NCT05195008: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Completed
1
72
Europe
BIIB113, BIIB113-Matching Placebo, 11^C]BIO-1819578
Biogen
Healthy Volunteer
07/23
07/23
SPYVAC01, NCT06145178: A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants

Recruiting
1
120
Europe
SPYVAC01
SpyBiotech Limited
Cytomegalovirus Infections
04/25
04/25
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Recruiting
1
130
Europe
GSK3862995B, Placebo
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
04/26
04/26
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Terminated
1
78
Europe, RoW
ARO-MUC5AC, Placebo
Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
11/24
11/24
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Completed
1
58
Europe
Placebo, AX-202
Arxx Therapeutics
Healthy Volunteers, Mild to Moderate Psoriasis
07/24
07/24
NCT06433921: A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

Recruiting
1
91
Europe
Salbutamol HFA-152a, Salbutamol HFA-134a, Placebo
GlaxoSmithKline
Asthma, Mild Asthma
03/25
03/25
Schmitt, Matthias
TEMPEST, NCT04706429 / 2020-002242-17: The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

Active, not recruiting
2
154
Europe
Trientine, Cufence, Placebo
Manchester University NHS Foundation Trust, National Institute for Health Research, United Kingdom, University of Manchester, University of Liverpool, Univar BV, University of Oxford
Hypertrophic Cardiomyopathy
04/24
10/24
Fox, David
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Butterfield, Stephen
No trials found
Telford, Karen J
No trials found
Felton, Timothy
No trials found
Cooksley, Tim
No trials found
Wang, Ran
No trials found

Download Options